114 related articles for article (PubMed ID: 32717738)
1. Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of Variability.
Dromain C; Sundin A; Najran P; Vidal Trueba H; Dioguardi Burgio M; Crona J; Opalinska M; Carvalho L; Franca R; Borg P; Vietti Violi N; Schaefer N; Lopez C; Pezzutti D; de Mestier L; Lamarca A; Costa F; Pavel M; Ronot M
Neuroendocrinology; 2021; 111(9):831-839. PubMed ID: 32717738
[TBL] [Abstract][Full Text] [Related]
2. Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A; Crona J; Ronot M; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Franca Bezerra RO; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Schaefer N; Sundin A; Costa F; Pavel M; Dromain C;
Oncologist; 2019 Nov; 24(11):e1082-e1090. PubMed ID: 30910869
[TBL] [Abstract][Full Text] [Related]
3. Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study.
Lamarca A; Ronot M; Moalla S; Crona J; Opalinska M; Lopez Lopez C; Pezzutti D; Najran P; Carvhalo L; Bezerra ROF; Borg P; Vietti Violi N; Vidal Trueba H; de Mestier L; Scaefer N; Baudin E; Sundin A; Costa F; Pavel M; Dromain C
Clin Cancer Res; 2019 Nov; 25(22):6692-6699. PubMed ID: 31375514
[TBL] [Abstract][Full Text] [Related]
4. Semi-quantitative visual assessment of hepatic tumor burden can reliably predict survival in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Ameli S; Pandey A; Khoshpouri P; Ghasabeh MA; Pandey P; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Nov; 29(11):5804-5812. PubMed ID: 31073860
[TBL] [Abstract][Full Text] [Related]
5. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.
Luo Y; Pandey A; Ghasabeh MA; Pandey P; Varzaneh FN; Zarghampour M; Khoshpouri P; Ameli S; Li Z; Hu D; Kamel IR
Eur Radiol; 2019 Oct; 29(10):5160-5171. PubMed ID: 30877462
[TBL] [Abstract][Full Text] [Related]
8. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Lamarca A; Barriuso J; Kulke M; Borbath I; Lenz HJ; Raoul JL; Meropol NJ; Lombard-Bohas C; Posey J; Faivre S; Raymond E; Valle JW
Br J Cancer; 2018 Jan; 118(2):181-188. PubMed ID: 29161241
[TBL] [Abstract][Full Text] [Related]
9. Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.
Ramtohul T; Cohen A; Rodrigues M; Piperno-Neumann S; Cabel L; Cassoux N; Lumbroso-Le Rouic L; Malaise D; Gardrat S; Pierron G; Mariani P; Servois V
Br J Cancer; 2022 Jul; 127(2):258-267. PubMed ID: 35347325
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of somatostatin receptor expressing tumor volume calculated from
Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide Alone or Combined with Capecitabine for the Treatment of Metastatic Neuroendocrine Neoplasia: A "Real-World" Data Analysis.
Bongiovanni A; Liverani C; Foca F; Fausti V; Di Menna G; Mercatali L; De Vita A; Riva N; Calpona S; Miserocchi G; Spadazzi C; Cocchi C; Ibrahim T
Neuroendocrinology; 2021; 111(9):895-906. PubMed ID: 33221806
[TBL] [Abstract][Full Text] [Related]
12. Survival predictors of
Swiha MM; Sutherland DEK; Sistani G; Khatami A; Abazid RM; Mujoomdar A; Wiseman DP; Romsa JG; Reid RH; Laidley DT
J Cancer Res Clin Oncol; 2022 Jan; 148(1):225-236. PubMed ID: 34110489
[TBL] [Abstract][Full Text] [Related]
13. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.
Liu E; Paulson S; Gulati A; Freudman J; Grosh W; Kafer S; Wickremesinghe PC; Salem RR; Bodei L
Oncologist; 2019 Jun; 24(6):783-790. PubMed ID: 30158287
[TBL] [Abstract][Full Text] [Related]
14. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
de Mestier L; Lamarca A; Hernando J; Zandee W; Alonso-Gordoa T; Perrier M; Walenkamp AM; Chakrabarty B; Landolfi S; Van Velthuysen MF; Kats-Ugurlu G; Caminoa A; Ronot M; Manoharan P; Garcia-Alvarez A; Brabander T; García Gómez-Muriel MI; Cadiot G; Couvelard A; Capdevila J; Pavel ME; Cros J
Endocr Relat Cancer; 2021 Jun; 28(8):549-561. PubMed ID: 34061764
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
17. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis.
Wang Y; Huang K; Chen J; Luo Y; Zhang Y; Jia Y; Xu L; Chen M; Huang B; Ni D; Li ZP; Feng ST
Contrast Media Mol Imaging; 2018; 2018():6037273. PubMed ID: 30510495
[TBL] [Abstract][Full Text] [Related]
18. [Value of tumor growth rate in evaluating the early therapeutic efficacy of neuroendocrine neoplasm].
Zhou YT; Xia YF; Li Y; Zhu YJ; Chi Y; Jiang L
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):1000-1006. PubMed ID: 35399019
[No Abstract] [Full Text] [Related]
19. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study.
Carmona-Bayonas A; Jiménez-Fonseca P; Lamarca Á; Barriuso J; Castaño Á; Benavent M; Alonso V; Riesco-Martínez MDC; Alonso-Gordoa T; Custodio A; Sánchez Cánovas M; Hernando Cubero J; López C; Lacasta A; Fernández Montes A; Marazuela M; Crespo G; Escudero P; Diaz JÁ; Feliciangeli E; Gallego J; Llanos M; Segura Á; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle JW; García-Carbonero R
J Clin Oncol; 2019 Oct; 37(28):2571-2580. PubMed ID: 31390276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
